TD Cowen assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report report published on Friday, Marketbeat Ratings reports. The firm issued an outperform rating on the biotechnology company’s stock. A number of other research firms also recently issued reports on ARWR. Sumitomo Mitsui Financial Group assumed coverage on shares […]
B. Riley reissued their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $55.00 price target on the biotechnology company’s stock. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at ($3.13) EPS. A number of other equities […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month […]
First Manhattan Co. lessened its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 7.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,025,654 shares of the biotechnology company’s stock after selling 79,933 shares during the quarter. First Manhattan Co. owned […]
Endurant Capital Management LP bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,187 shares of the biotechnology company’s stock, valued at approximately $1,143,000. Several other large investors have […]